In a letter last week, patient advocacy group Patients for Affordable Drugs called on the Federal Trade Commission (FTC) to examine whether a pay-for-delay deal allegedly struck between reference adalimumab (Humira) manufacturer AbbVie with biosimilar developer Samsung Bioepis violates anti-competitive and antitrust laws.
In a letter last week, patient advocacy group Patients for Affordable Drugs (P4AD) called on the Federal Trade Commission (FTC) to examine whether a pay-for-delay deal allegedly struck between reference adalimumab (Humira) manufacturer AbbVie with biosimilar developer Samsung Bioepis violates anti-competitive and antitrust laws.
The deal is the second agreement AbbVie has made for the blockbuster anti—tumor necrosis factor therapy since 2017. The first agreement was made with drug manufacturer Amgen, staving off the US market entry of its adalimumab biosimilar until 2023. This most recent deal with Samsung Bioepis, which involves the same date for US market entry as the Amgen deal, gives the pharmaceutical company 5 more years without biosimilar competition. Samsung Bioepis' proposed biosimilar, SB5, has not yet been approved by the FDA.
“AbbVie is using pay-for-delay deals to keep a cheaper generic off the market and patients are the victims. We believe it is illegal and anti-competitive, and we are asking the FTC to step in and protect patients from AbbVie’s price hikes,” said David Mitchell, president and co-founder of P4AD, in a statement.
P4AD’s letter was sent to the acting chairwoman of the FTC and to lawmakers, including leaders of the Senate and House Appropriations Committees. Signed by Mitchell, the letter addressed the cost of Humira and the harm it its high pricing has caused to the patients who depend on the drug.
“Humira is incredibly expensive and costs patients and taxpayers billions. Over the past 5 years, the price has more than doubled. Its most recent price increase of 9.7% in January of this year will cost the US healthcare system $1.2 billion. We have patients all over the country who are hurt by these pay-for-delay deals,” the letter reads.
Conversely, AbbVie has strongly objected to use the term “pay-for-delay” to describe the adalimumab agreements. In a statement, the company said “AbbVie’s settlements with Amgen and Samsung Bioepis are in no way pay-for-delay arrangements. AbbVie is not paying Amgen or Samsung Bioepis, and in fact both Amgen and Samsung Bioepis will be paying royalties to AbbVie once their adalimumab biosimilar products launch in the [United States].”
In addition to the letter, P4AD also encouraged patients to write to their senators in support of changes that would put an end to such settlements, and says that, to date, more than 1200 patients have written to show their support.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.